Zyneyro ApS: Financial statements 2022
CVR: 42057428
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Zyneyro ApS (CVR 42057428) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -27,036 and a net result of DKK -28,481 compared with DKK -29,101 the year before. Equity in the 2022 report amounted to DKK -17,582.
- Gross Profit
- DKK -27,036
- Profit/Loss
- DKK -28,481
- Equity
- DKK -17,582
- Total Assets
- DKK 857,284
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -27 t. | -28 t. | -18 t. | 0 |
| 2021 | - | -27 t. | -29 t. | 11 t. | 0 |
Official annual report
Keep an eye on Zyneyro ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Zyneyro ApS has published its annual report for 2021. Gross profit came to DKK -27,125, and the net result was DKK -29,101.
About Zyneyro ApS
Zyneyro ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2021. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named DolorestBio ApS. The management consists of Steen Søren Klysner. The board consists of Jacob Ørndrup (chair), Andreas Toft Sørensen, Erik Vinther and Kenneth Lindegaard Madsen. The company's owners include Marigold Innovation ApS, IFO ApS and UGether ApS. The company has 10 employees (2026). In 2025, the company reported a gross profit of DKK -4,550,684 and a net result of DKK -7,466,446 compared with DKK 665,931 the year before. Equity in the 2025 report amounted to DKK 4,147,370.